Product Description
Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It's a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs. It depends on the type of cancer you have as to which drugs you have it with. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/oxaliplatin-eloxatin)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 93
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Biliary Tract Cancer|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Esophageal Cancer|Gastrointestinal Cancer|Lymphoma, Non-Hodgkin|Pancreatic Cancer
Phase 2: Bladder Cancer|Breast Cancer|Chemical and Drug Induced Liver Injury|Cholangiocarcinoma|Digestive System Cancer|Esophageal Diseases|Gallbladder Cancer|Hepatic Veno-Occlusive Disease|Hepatocellular Carcinoma|Intestinal Diseases|Liver Cancer|Lung Cancer|Lymphoma, B-Cell|Pancreatic Ductal Carcinoma|Peritoneal Cancer|Squamous Cell Carcinoma|Stomach Diseases
Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06225622 |
CSPC-DEY-CRC-K01 | P1 |
Recruiting |
Colorectal Cancer |
2026-01-01 |
21% |
2024-11-27 |
Primary Endpoints|Treatments |
CTR20200664 |
CTR20200664 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-06-08 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12619001723178p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Muscle Spasticity|Epilepsy |
2020-02-24 |
|||
NCT06258525 |
IIT2022-11-Gangi-SAMe | P2 |
Not yet recruiting |
Colorectal Cancer|Liver Cancer|Hepatic Veno-Occlusive Disease|Chemical and Drug Induced Liver Injury |
2028-04-01 |
2% |
2025-11-05 |
|
NCT07146646 |
CASE2225 | P2 |
Recruiting |
Cholangiocarcinoma|Gallbladder Cancer|Biliary Tract Cancer |
2027-02-01 |
2025-11-13 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06806033 |
GO45434 | P2 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2027-01-31 |
12% |
2025-12-24 |
Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT05476796 |
LOGICAN | P2 |
Recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2026-01-01 |
41% |
2023-10-18 |
Primary Endpoints|Start Date|Treatments |
NCT06247956 |
SHR-8068-201-GC | P2 |
Active, not recruiting |
Squamous Cell Carcinoma|Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2025-12-30 |
2% |
2025-09-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT04469556 |
PASS-01 | P2 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer |
2025-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT05494060 |
EXPLORING | P2 |
Recruiting |
Adenocarcinoma|Esophageal Diseases|Gastrointestinal Cancer|Stomach Diseases|Intestinal Diseases|Digestive System Cancer|Esophageal Cancer |
2024-12-01 |
41% |
2023-11-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04430738 |
SGNTUC-024 | P2 |
Active, not recruiting |
Gastrointestinal Cancer|Adenocarcinoma|Colorectal Cancer|Cholangiocarcinoma|Esophageal Cancer|Bladder Cancer |
2024-07-31 |
12% |
2025-09-10 |
Primary Endpoints |
2017-000927-29 |
CRC-PIPAC | P2 |
Active, not recruiting |
Peritoneal Cancer|Colorectal Cancer |
2020-01-31 |
2022-03-13 |
Treatments |
|
NCT06571461 |
HE072-006 | P3 |
Not yet recruiting |
Pancreatic Cancer |
2028-01-01 |
17% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT06929624 |
SHR-A1912-301 | P3 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2027-03-01 |
71% |
2025-05-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06624085 |
GO44900 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2030-03-31 |
50% |
2025-06-05 |
Primary Completion Date|Primary Endpoints|Treatments |
2023-509814-12-00 |
2023-509814-12-00 | P2 |
Recruiting |
Colorectal Cancer |
2031-03-31 |
2025-05-02 |
||
2020-003134-20 |
MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |
2022-03-13 |
Treatments |
|
NCT07281768 |
J25118 | P2 |
Not yet recruiting |
Colorectal Cancer|Adenocarcinoma |
2030-03-01 |
12% |
2025-12-16 |
Primary Endpoints|Treatments |
2024-516791-15-00 |
GO45434 | P2 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2029-04-30 |
2025-05-02 |
Treatments |
|
NCT07238283 |
HR070803-308 | P3 |
Recruiting |
Pancreatic Cancer |
2028-10-01 |
2025-12-11 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06521255 |
ICP-CL-00903 | P3 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2028-09-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
2020-002141-42 |
PelvEx II | P3 |
Active, not recruiting |
Colorectal Cancer |
2028-07-03 |
2022-03-13 |
Treatments |
|
NCT04495088 |
ACO/ARO/AIO-18.2 | P3 |
Recruiting |
Colorectal Cancer |
2030-08-01 |
2020-11-13 |
Primary Endpoints|Start Date |
|
NCT06205485 |
NEO-RT | P3 |
Recruiting |
Colorectal Cancer |
2030-01-30 |
2024-08-14 |
Primary Endpoints|Start Date |
|
2022-501181-22-01 |
STEREOPAC-001 | P2 |
Recruiting |
Adenocarcinoma|Pancreatic Cancer |
2032-10-01 |
2025-05-02 |
Treatments |